Fig. 3
MGLL potentiates proinflammatory cytokine expression in tumor-associated macrophages. a Quantification of M1-like and M2-like TAMs in MC-38 tumors which were subcutaneously inoculated for 3 weeks in WT or TgMGLL mice. Each tested sample was pooled from five individual ones. The M1-like TAMs were assed as CD3-CD45R-Gr1-GFP-CD45+F4/80+CD11c+CD206-; The M2-like TAMs were assed as CD3-CD45R-Gr1-GFP-CD45+F4/80+CD206+CD11c-. The inoculated MC-38 cells were stably marked with GFP. This test was repeated three times. Representative results were displayed. b mRNA expression of cytokines, as indicated, in the TAMs from WT or TgMGLL mice were measured dynamically (n = 5, ***P < 0.005). c MGLL potentiates M1 and blocks M2 activation of macrophages. The BMDMs from WT or TgMGLL mice were treated with IFNγ (10 ng ml−1) + LPS (100 ng ml−1) or IL-4 (10 ng ml−1) for 6 h and then subjected to real-time PCR assays (n = 4, **P < 0.01, ***P < 0.005). d mRNA levels of cytokines in the fl/fl or Mac-mgll-KO mice-derived BMDMs treated with IFNγ (10 ng ml−1) + LPS (100 ng ml−1) or IL-4 (10 ng ml−1) for 6 h (n = 4, **P < 0.01, ***P < 0.005). Data in b–d represent the means ± s.e.ms. (Student’s t-test)
